I/ INTRODUCTION
Molecular imaging can be used as a non-invasive means to evaluate pathophysiological processes, such as cancer, in rodents. Indeed, these techniques provide real-time information for early diagnosis, allow longitudinal follow-up of tumor development, and facilitate studies of therapeutic activity and antitumor efficacy of new anti-cancer drugs. Because drug development is an expensive and complicated process with an extremely slim chance of success for any given molecule, molecular imaging can play an important role in drug discovery in the laboratory, during the translation phase from in vitro assays to preclinical systems, and eventually in evaluating the biodistribution, pharmacokinetics and biological activity of potentially therapeutics molecules [1] .
These applications necessitate the generation of suitable imaging devices and imaging probes.
This review presents the most commonly used methods for small animal imaging. We will focus mainly on optical imaging techniques and probes that are actively being developed for their sensitivity, inherent biological safely, and relative ease of use (see Table 1 ). In addition, we will present the translation of novel optical devices, methods and techniques into the clinic, which are areas of increased interest.
II/ COMMONLY USED SMALL ANIMAL IMAGING TECHNOLOGIES 1/ X-ray computed tomography (CT)
CT is very commonly used on human patients, but until recently its application in rodents has been limited by its spatial resolution. X-rays are absorbed to varying degrees by different 6 biological tissues. Recently, micro-CT devices have been developed to image rodents with a spatial resolution ranging from 10-100 µm [2] . Micro-CT is a powerful and cost-effective method for imaging soft-tissue structures, skeletal abnormalities and tumors. Micro-CT systems provide excellent sensitivity for skeletal tissue (Table 1) .
2/ Magnetic resonance imaging (MRI)
MRI is another standard method of clinical imaging, and recent improvements and adaptations have expanded its use to specialized animal facilities.
1 H-MRI is based on the fact that when a sample lying within a magnetic field is subjected to a radio-frequency pulse its protons absorb energy and generate a detectable signal during the relaxation phase. The strength of the signal is a function of the number of protons. The relaxation process can be described by two fundamental rate constants: T1 (longitudinal relaxation) and T2 (transverse relaxation) [3] . The sensitivity of this method is low (mM concentrations) but its spatial resolution is extremely good (µm). MRI is very useful for detecting tumors and measuring morphologic parameters. Because there is no damaging radiation, multiple imaging sessions can be performed safely, allowing longitudinal follow-up of tumor growth. Finally, contrast agents influencing either the T1 or T2 relaxation time constants are being developed to allow functional imaging [4] [5] [6] [7] . Tc. Positrons move a short distance through tissues, losing energy as they collide with other molecules, and eventually combine with electrons ("annihilation"), producing two highenergy gamma rays or photons traveling outward and in opposite directions. In SPECT, a single photon per event is directly emitted, and this photon interacts with electrons and nuclei of nearby atoms within the tissue. Unlike positrons, these energetic photons do not "slow down" but are attenuated. Because there is only one photon per event, electronic collimation is not possible, and a physical collimator must be added. Sensitivities are on the order of 10 -14 -10 -15 M for PET and 10 -14 M for SPECT, and spatial resolution can reach 1.3 mm for PET and is sub-millimetric for SPECT [9] . PET and SPECT give information about physiological functions at the molecular level and are thus well suited to monitoring many vital processes, such as glucose metabolism, blood flow and perfusion, receptor-ligand binding rates, and oxygen utilization.
3/ PET and SPECT

4/ Optical imaging
Optical imaging is based on the detection of light passing through the tissues. Several major obstacles must be resolved for optical imaging, including surface reflectance, absorption, scattering (deviation of the photon from its original path) and autofluorescence. Absorption and autofluorescence are important factors in fluorescence imaging in the visible wavelengths (400-650 nm) but are less problematic in the near-infrared (NIR) (650-900 nm). Above 900 nm, however, water absorption is an issue because it prevents deep penetration of the light.
Absorption is affected by the thickness and optical properties of the tissues. The body heterogeneity will compromise the linearity of measurements. In vivo, scattering of far-red photons affects the spatial resolution, which is dependent on the depth of observation. Spatial resolution is mainly affected by an animal's skin, which reflects light, but intravital microscopy greatly improves the resolution [1] .
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Light can be produced in live animals by two main types of reaction: bioluminescence (BLI) and fluorescence (for reviews see [10, 11] in vivo and temporal resolution is in the range of milliseconds to seconds. However, 2D-FRI is highly surface-weighted, and quantification is at best semi-quantitative.
Recent development of 2D-FRI may allow its application in the clinic for improving cancer surgery. The Fluobeam ® system (Fluoptics, Grenoble, France) uses a laser and small chargecoupled device (CCD) camera within a portable 2D-FRI system. It can function under the normal light of an operating room [12] . Another intraoperative device, the FLARE system (fluorescence-assisted resection and exploration), has already been used in pre-clinical trials [13] [14] [15] .
Because of problems with absorption and autofluorescence, deep and absorbing tissues like lung, spleen or liver cannot be investigated non-invasively using 2D-FRI. Imaging these tissues requires the use of fluorescence molecular tomography (FMT) [16] . FMT provides 3D volumetric imaging, true quantification independent of depth, tissue optical properties and heterogeneity, and augmentation of the contrast by reducing the autofluorescence. Detecting deep events requires transillumination to avoid autofluorescence [17] . Transillumination can be done using a simple optical bench adapted to continuous wave acquisitions [18] [19] [20] calculates and analyzes the time that each photon travels, whereas the photons are "simply" captured by the CCD as they arrive in continuous acquisition. This method will soon be transferred to the clinic for imaging deep events [21] . Recent work suggests that a fluorescent signal can be obtained in samples 2 to 5-cm thick, which could be sufficient, for example, for prostate imaging.
III/ FLUORESCENT OPTICAL PROBES
As mentioned above, optical imaging of small animals requires the use of imaging devices and of fluorescent probes adapted to functional imaging. Several types of probes can be classified into three different categories, as summarized by R Weilssleider [22] . The simplest probes are usually large molecules that remain in circulation in the blood and can provide information about physiological processes, such as changes in blood volume, perfusion and angiogenesis. The second probe category targets a specific molecule, including receptors for somatostatin, epidermal growth factor (EGF), integrins, folate, or antigen-targeted antibodies, and can be used to visualize pathological tissues and/or monitor the expression level of a target. The third group of probes is composed of "smart-probes" that undergo a change in optical properties when in contact with their targets (Fig. 2) . These activatable probes are well adapted for detecting thio-reductases, proteases, such as matrix metalloproteinases (MMPs), cathepsins, caspases, or other enzymes and physicochemical parameters. In this chapter, we will focus on "targeted" and "activatable" probes; finally, we will describe the use of nanoparticles as optical imaging tools.
1/ Receptor-targeted probes
Early diagnostics and image-guided tumor surgery are two key objectives of optical imaging. Probes containing the Arg-Gly-Asp motif (RGD) have been intensively developed to follow expression of integrin  v  3 [26] , a protein that is expressed by the neo-endothelial cells that form tumor blood vessels and is also frequently overexpressed on tumor cells themselves, such as in lung cancers [27, 28] , melanomas [29, 30] , brain tumors [31] or breast cancers [32] . to the monomeric molecule [34] [35] [36] [37] [38] [39] . Because of their specific targeting properties, RGD probes can be used to monitor the efficacy of an anti-integrin or anti-angiogenic treatment non-invasively and in real time, as demonstrated in an orthotopic glioblastoma model [40] . In our laboratory, we also showed the utility of visualizing the multimeric RAFT-cRGD molecule using the portable intraoperative Fluobeam ® imaging device to improved the quality and outcome of tumor surgery (Fig. 1 ) [12] .
Monitoring the efficacy of recently developed anti-EGF receptor (EGFR) cancer treatments is of the utmost importance. To assess EGF binding/anti-EGF treatments efficacy and cell viability, anti-EGFR coupled with IRDye® 800 CW (LI-COR, NIR800) and annexin-V coupled with IRDye® 700DX (LI-COR, NIR700) were used to follow EGFR expression in colorectal tumors-bearing mice [41] . This study showed that anti-EGF-NIR800 accumulated more actively in tumors expressing high levels of EGFR and, annexin-V-NIR700 staining intensity was elevated in sensitive tumors treated with cetuximab compared to control groups.
These imaging approaches may prove useful for serial, noninvasive monitoring of the biological effects of EGFR inhibition in preclinical studies and may also be adapted for clinical use. As described for cRGD, cyanine 5.5-labeled cetuximab has also been used to improve tumor resection and margin prevention in head and neck carcinomas [42] .
2/ Activatable molecules for fluorescent imaging
Optical imaging is the method of choice for functional, real-time, in vivo monitoring because it provides an "easy" approach for measuring enzymatic activities, thus enabling researchers to follow, for example, the activation of signal transduction pathways, target gene expression and drug-target interactions [43] . It also allows the in vivo analysis of drug efficacy and pharmacodynamic properties.
Several proteases are overexpressed or activated during cancer progression and are thus attractive targets for the so-called "smart" probes, also known as activatable molecules (Fig.   2 ). Activatable means that a change in signal intensity or wavelength can be detected in response to the interaction of the probe with its target [19, 44] . Activatable molecules have several advantages, including minimal non-specific background and improved contrast in the targeted organ [43, [45] [46] . Proteases were the first enzymes to be targeted in this way, as described for cathepsins (cathepsin B and cathepsin D for cancer progression and cathepsin K for the detection of osteoclasts), caspases-1 and -3 (indicators of apoptosis) and MMPs 2, -7, -9, and -14 (inflammation and cancer) [22, [47] [48] [49] . Because the signals produced by these probes are a direct function of their biological activity, smart probes can be used to measure the activity of a drug on its target [50] [51] [52] [53] [54] .
One of the first NIR activatable probes, described by Weissleder and colleagues, is a polymer of poly-L-lysine and methoxypolyethylene glycol succinate [55] . This probe has a long circulation time, and its fluorescence is quenched in the presence of a high concentration of 13 fluorescent molecules. A detectable NIR signal is (re)-generated when these self-quenched molecules are digested by lysosomal proteases after internalization in the target tumor cells, allowing the detection of sub-millimeter-sized nodules. A similar strategy was used to detect cathepsin B, K, L, and S in cardiac pathologies [56] and image cancer in mouse model of adenoma of the gastrointestinal track [57] , or rhabdomyosarcoma [58] .
In vivo monitoring of apoptosis is also of great interest. Using a self-quenched caspaseactivatable peptide (TcapQ647), Bullok et al. measured in vivo apoptosis that was induced by bacterial infection. Activation of the probe was confirmed by ex-vivo TUNEL analysis of the tissues and by detection of activated caspase-3 [59] . However, good enzymatic specificity is still an issue facing this technique. For example, it is difficult to design a caspase-specific probe that has low cross-reactivity for cathepsins or legumain. To circumvent this problem,
Edgington and colleagues developed NIR activity-based molecules that form permanent covalent bonds with target proteases, based on acyloxymethyl ketone (AOMK) probes. These probes can be used to monitor early stages of apoptosis using whole-body, noninvasive optical imaging, as demonstrated in human colorectal tumors-bearing mice [60] .
The search for new drugs capable of inhibiting receptor tyrosine kinases (RTK) such as EGFR is currently a major issue for cancer treatment. To assess drug efficiency against EGFR, a novel bioluminescent-based approach using a bifragment luciferase reconstitution system was recently reported [61] . EGFR and its interacting partner proteins were fused to the NH2-and COOH-terminal fragments of firefly luciferase. This method allowed the identification and quantification of EGFR activation in mice before and after anti-EGFR treatments, such as gefitinib or radiotherapy. This technique is a promising tool that could enhance the preclinical evaluation of novel RTK-targeted therapeutics.
Other activatable compounds have been developed to target viable cancer cells. Urano et al.
made a pH-activatable probe coupled to the anti-HER-2 monoclonal antibody trastuzumab. In mice bearing subcutaneous tumors, the probe was highly specific for HER-2-positive tumors with a minimal background signal. Because the energy-consuming proton pumps maintain an acidic pH in lysosomes, only viable HER-2-positive cancer cells showed a high signal [62] .
The intracellular redox environments of viable cells can also be used to design probes in which fluorescence will be released after rupture of a disulfide bridge during following internalization. Our group used this method to design RGD-based targeted probes that allow the tracking of a pro-apoptotic toxic peptide released within the target cells [63] [64] [65] [66] .
3/ Nanoparticles developed for in vivo applications
During the last few years, a wide variety of nanoparticles were developed as contrast agents for in vivo fluorescence imaging applications. Due to their size, these particles offer new structural and optical properties. They have better signal intensity than organic fluorophores, enabling detection of weakly expressed targeted biomarkers. In addition, because of their relatively large surface area, nanoparticles can accommodate multiple probes, enabling multivalent targeting of several biomarkers and thus increasing the affinity of each individual probe. All of these properties make nanoparticles good candidates for biomedical imaging, therapeutic applications or a combination of both (theranostics).
Quantum dots (QDs) are the most extensively described and studied nanoparticles [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] .
These small nanocrystals are made of semiconductive material and have an emission color that can be precisely tuned by adjusting their composition and size [77] . They can thus be used across a wide spectrum, from the ultraviolet to the NIR and are also photostable and extremely bright [78] . Recently, QDs were also encapsulated in phospholipid micelles to image tumors [79, 80] . The encapsulation of QDs enhanced their biodistribution and their passive accumulation in tumors. Various nanoparticles have also been developed for in vivo fluorescence imaging applications: these nanoparticles include gold nanoparticles [81, 82] , hybrid nanoparticles [83] [84] [85] [86] , C dots [87] , lipid nanoparticles [88] , liposomes [89] , polymeric nanoparticles [90, 91] , and biodegradable luminescent porous silicon nanoparticles [92] .
Several applications have been developed using these new contrast agents. In 2004, Kim et al.
demonstrated that QDs translocated to sentinel lymph nodes after intra-dermal injection, likely due to a combination of passive flow in lymphatic vessels and active migration of dendritic cells that had engulfed the nanoparticles [70] . This application could have a great clinical impact, enabling surgeons to rapidly identify and excise draining lymph nodes from tumors for staging cancer using optical guided surgery [93] . The major limitation of QDs is their possible toxicity, which thus far precludes their use in humans. A recent study found no appreciable toxicity of QD, even after their breakdown in vivo [94] ; however, because of their different chemical formulations and nanoparticle structures, the absence of toxicity of each type of QD, as well as that of each of its byproducts, must be very carefully investigated.
Currently, this technique has been used to localize various cancers in animal models, including subcutaneous tumors [95] , lungs [71, 72] , esophagus [73] , and head and neck [76] .
The key challenge for in vivo imaging applications is to develop nanoparticles with an optimized biodistribution. Several studies have shown the particular importance of particle size, PEGylation and surface coating. These properties affect the mean of accumulation in and elimination from tumors through the enhanced permeability and retention (EPR) effect (Fig.   3 ) [83, [95] [96] . Indeed, during tumor-induced angiogenesis, blood vessels are abnormal and present large pores, allowing the extravasation of macromolecules up to 400 nm in size, that can accumulate in the tumor microenvironment [97] . This EPR effect has inspired the development of a variety of nanoparticles to treat and image tumors. Several groups have studied the biodistribution of hydrophobically modified glycol chitosan nanoparticles loaded with cisplatin, camptothecin or paclitaxel by in vivo NIR imaging [98] [99] [100] . These groups have found a passive but specific accumulation in subcutaneous tumors due to the EPR effect, as well as increased effectiveness of encapsulated drugs compared to free drugs.
To improve the tumor targeting selectivity, specific ligands can be grafted onto the surface of nanoparticles. Again, one of the most commonly described ligands for tumor targeting is the RGD peptide [69, 75, 101] , though several specific other tumor ligands have also been investigated. In vivo targeted imaging was demonstrated in a mouse model, using a copolymer functionalized QD conjugated to an antibody that targets a prostate-specific membrane antigen [68] . Gold nanoparticles labeled with anti-EGFR monoclonal antibodies also have a large range of potential applications, from the cellular to the animal levels [81] . Lee et al. Finally, nanoprobes can also be powerful tools for evaluating the efficiency of targeted cancer therapies. Medarova et al. [104] described a tumor-specific contrast agent (iron oxide nanoparticles labeled with Cy5.5 dye) targeting underglycolated mucin 1 (uMUC-1), a tumor antigen present on more than 90% of breast cancers and predictive of chemotherapeutic response. After doxorubicin treatment, nanoparticle probes were present at a lower level in the treated tumors compared to untreated tumors, reflecting the reduced expression of uMUC-1.
To confirm these findings, similar results were obtained using in vivo fluorescence imaging and MRI. The same kind of nanoparticle was also used to deliver small interfering RNA (siRNA) in vivo and track their successful delivery by non-invasive imaging [105] .
In conclusion, nano-sized contrast agents offer several advantages over conventional agents because they can be passively targeted to the tumors via the EPR effect or actively targeted by specific ligands. Most importantly, nanoparticles offer multifunctionality, such as combining imaging and drug (or siRNA) delivery or, providing dual-modality imaging that combines NIR and either MRI or PET [106] . Thus, these nanoparticles promise great versatility in the detection and treatment of diseases.
IV/ CONCLUSION
Optical imaging is an inexpensive, easy-to-use, and non-radiative tool that can provide rapid semi-qualitative (2D), quantitative (3D), and functional information from the cellular to the several centimeter scale. Fluorescence molecular tomography is the preferred method for quantifying protein levels and enzymatic activities. 2D-fluorescent reflectance optical imaging is poised to be the premier approach in molecular imaging, especially for researchers who are not specialists in medical imaging or who do not have access to a nuclear medicine facility or very expensive magnets. However, the future of cancer imaging in mice will rely on the development of a large collection of highly specific tracers or smart contrasting agents.
Coupling high-resolution methods like micro-CT or MRI with highly sensitive techniques adapted to functional imaging, such as PET, SPECT or optical imaging, will soon open new frontiers in the study of cancer in small animals and will provide efficient tools for evaluating new treatments. Importantly, a major bottleneck that inhibits the widespread application and generation of these probes concerns the use of NIR fluorophores in human clinical trials by legal agencies. In response to this issue, the FDA recently established the Process Analytical Technologies initiative, which will certainly facilitate the manufacture and use of NIR probes. 
